TY - JOUR T1 - The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma JF - Anticancer Research JO - Anticancer Res SP - 6585 LP - 6592 VL - 36 IS - 12 AU - YUKI HAYASHI AU - JUNPEI YAMAGUCHI AU - TOSHIO KOKURYO AU - TOMOKI EBATA AU - YUKIHIRO YOKOYAMA AU - TSUYOSHI IGAMI AU - GEN SUGAWARA AU - MASATO NAGINO Y1 - 2016/12/01 UR - http://ar.iiarjournals.org/content/36/12/6585.abstract N2 - Background: Although the survival of patients with cholangiocarcinoma has improved, the prognosis remains unfavorable. The overexpression of mesenchymal–epithelial transition factor (MET) and recepteur d'origine nantais (RON) has been considered to be indicative of a poor prognosis in some types of cancer. On the other hand, some studies have shown that the expression of MET and RON is a favorable prognostic factor in certain types of tumors. Materials and Methods. Based on the immunohistochemical analysis of MET and RON, 290 patients who underwent resection for extrahepatic cholangiocarcinoma were divided into three groups: MET/RON-negative, -intermediate, and -positive. The associations between MET/RON expression and clinicopathological features, including prognosis, were analyzed. Results: MET/RON-negativity was associated with nodal metastasis and advanced pathological stage. The overall 5-year survival rates were significantly lower in the MET/RON-negative and MET/RON-positive groups than in the MET/RON-intermediate group (28.3%, 32.4% and 48.5%, respectively; p=0.01). Conclusion: The complete loss of one or both MET and RON, as well as their overexpression, is a poor prognostic factor in patients with extrahepatic cholangiocarcinoma, probably due to the high rate of lymph-node metastasis. ER -